Chondrosarcoma

Chondrosarcoma (CSA) is a malignant mesenchymal neoplasm characterized by the production of cartilaginous matrix by tumor cells. It is the second most common primary bone tumor in dogs, accounting for approximately 5-10% of all primary bone sarcomas. In cats, it is rare but can occur. Chondrosarcoma can arise centrally within the medullary cavity (central or medullary CSA), on the bone surface (periosteal or juxtacortical CSA), or in soft tissues (extraskeletal CSA). In veterinary patients, the most common sites are the nasal cavity and paranasal sinuses, followed by the appendicular skeleton (long bones, especially the proximal humerus and distal femur), ribs, and pelvis. The tumor is locally aggressive, with a high rate of recurrence after incomplete excision, but a lower metastatic potential compared to osteosarcoma. Histological grading (I, II, III) based on cellularity, pleomorphism, and mitotic index correlates with biological behavior. Surgical resection with wide margins is the treatment of choice, and adjuvant therapy may be considered for high-grade tumors or incomplete margins.

The exact etiology of chondrosarcoma is unknown, but several factors have been implicated. Genetic mutations and chromosomal aberrations, such as alterations in the p53 tumor suppressor gene and overexpression of growth factors like insulin-like growth factor (IGF) and platelet-derived growth factor (PDGF), may play a role in tumorigenesis. Chronic inflammation, trauma, and pre-existing benign cartilaginous lesions (e.g., osteochondromatosis, enchondromas) have been suggested as predisposing factors, though evidence is limited. In dogs, no specific viral or environmental causes have been identified. The tumor arises from primitive mesenchymal cells that differentiate toward chondroblasts, producing a cartilaginous matrix. In the nasal cavity, chronic rhinitis or exposure to environmental carcinogens (e.g., tobacco smoke, pesticides) may increase risk, but definitive associations are lacking. In the appendicular skeleton, no clear biomechanical or traumatic trigger has been established. Extraskeletal CSA may arise from metaplastic cartilage in soft tissues, often in the mammary gland, skin, or other sites, but the cause is unknown.

Chondrosarcoma primarily affects middle-aged to older dogs, with a median age of 7-9 years. There is no strong sex predilection, though some studies suggest a slight male predominance. Large and giant breeds, such as Golden Retrievers, Labrador Retrievers, German Shepherd Dogs, Boxers, and Rottweilers, are overrepresented, likely due to their size and genetic predisposition. In cats, chondrosarcoma is rare, with a median age of 10-12 years, and no breed predilection. The nasal form is more common in dolichocephalic breeds (e.g., Collies, Greyhounds) due to their elongated nasal passages, while the appendicular form is more common in large breeds. The tumor accounts for about 10% of primary bone tumors in dogs, with an estimated incidence of 0.2-0.5 per 100,000 dogs. Rib chondrosarcoma is the most common primary rib tumor in dogs. Metastasis occurs in 10-20% of cases, primarily to the lungs, and is more frequent with high-grade tumors. The overall prognosis is better than for osteosarcoma, with a median survival time of 1-3 years after aggressive surgical resection.

Chondrosarcoma arises from mesenchymal cells that produce a hyaline cartilage matrix. The tumor grows by expansion and infiltration, causing bone destruction and cortical thinning. In the appendicular skeleton, the tumor typically originates in the medullary cavity, eroding the endosteal surface and eventually breaking through the cortex into the surrounding soft tissues. This leads to pathological fracture, pain, and lameness. In the nasal cavity, the tumor fills the nasal passages, causing obstruction, epistaxis, and facial deformity. The tumor is locally invasive, often extending into adjacent structures such as the orbit, cribriform plate, or cranial vault. Histologically, the tumor is composed of lobules of neoplastic chondrocytes with varying degrees of cellularity, pleomorphism, and mitotic activity. Low-grade tumors (grade I) are well-differentiated, with abundant cartilaginous matrix and low mitotic index, while high-grade tumors (grade III) are poorly differentiated, with high cellularity, nuclear atypia, and mitotic activity. The tumor's growth rate is generally slower than osteosarcoma, but it can be aggressive locally. Metastasis occurs hematogenously, most commonly to the lungs, and less frequently to regional lymph nodes or other bones. The tumor's ability to metastasize is correlated with histological grade, with high-grade tumors having a higher metastatic rate.

Intrinsic factors include age (middle-aged to older dogs), breed (large and giant breeds), and genetic predisposition. Certain breeds, such as Golden Retrievers and Rottweilers, have a higher incidence, suggesting a hereditary component. Extrinsic factors include chronic inflammation, trauma, and exposure to environmental carcinogens. In the nasal cavity, chronic rhinitis or exposure to tobacco smoke may increase risk. Prior radiation therapy for other conditions has been associated with the development of sarcomas, including chondrosarcoma, in some cases. Obesity and high body weight may increase the risk of appendicular tumors due to increased mechanical stress on bones. There is no evidence that diet or exercise directly causes chondrosarcoma, but they may influence overall health and immune surveillance.

Clinical signs depend on the location of the tumor. Appendicular chondrosarcoma presents with progressive lameness, swelling, and pain at the affected site. The lameness may be intermittent initially, becoming persistent and severe as the tumor grows. Palpation may reveal a firm, painful mass, and pathological fracture can cause acute, non-weight-bearing lameness. Nasal chondrosarcoma presents with unilateral or bilateral epistaxis, nasal discharge, sneezing, stertor, and facial deformity. As the tumor invades the cribriform plate, neurological signs such as seizures, circling, or behavioral changes may occur. Rib chondrosarcoma may present as a palpable thoracic wall mass, often incidental, with or without pain. Pelvic chondrosarcoma can cause tenesmus, dyschezia, or lameness due to compression of the rectum or sciatic nerve. Systemic signs such as lethargy, anorexia, and weight loss are uncommon but may occur with advanced disease or metastasis. On physical examination, a firm, fixed mass may be palpable, and regional lymph nodes may be enlarged if metastasis has occurred.

Differential diagnoses for appendicular chondrosarcoma include osteosarcoma, fibrosarcoma, hemangiosarcoma, and other primary bone tumors. Osteosarcoma is the most common primary bone tumor and is more aggressive, with a higher metastatic rate. Radiographically, osteosarcoma often shows a sunburst or Codman's triangle periosteal reaction, while chondrosarcoma may have a more mixed pattern with areas of mineralization. Fibrosarcoma and hemangiosarcoma are less common and may have similar radiographic features. Benign bone lesions such as bone cysts, osteomyelitis, and eosinophilic panosteitis should also be considered. For nasal chondrosarcoma, differentials include nasal adenocarcinoma, squamous cell carcinoma, fibrosarcoma, and lymphoma. These can be differentiated by biopsy and histopathology. Rib chondrosarcoma should be differentiated from other thoracic wall tumors such as osteosarcoma, fibrosarcoma, and hemangiosarcoma. Extraskeletal chondrosarcoma must be distinguished from other soft tissue sarcomas, such as liposarcoma or malignant fibrous histiocytoma, via histopathology.

The diagnostic workup for suspected chondrosarcoma begins with a thorough history and physical examination, including orthopedic and neurological evaluation. For appendicular tumors, radiographs of the affected bone are obtained, including orthogonal views. Radiographic features suggestive of chondrosarcoma include a mixed lytic-proliferative lesion with cortical destruction, periosteal reaction, and soft tissue swelling. However, radiographs cannot definitively differentiate chondrosarcoma from other bone tumors. Thoracic radiographs are essential to screen for pulmonary metastasis. Advanced imaging, such as computed tomography (CT) or magnetic resonance imaging (MRI), is recommended to assess the extent of the tumor, particularly for nasal and pelvic tumors. CT provides excellent bone detail and is useful for surgical planning. MRI is superior for evaluating soft tissue extension and intramedullary involvement. A bone scan (scintigraphy) may be used to detect skeletal metastasis. Definitive diagnosis requires biopsy. A core needle biopsy or incisional biopsy is preferred to obtain a representative sample. The biopsy should be taken from the center of the lesion, avoiding necrotic areas. Histopathology confirms the diagnosis and provides the histological grade. For nasal tumors, rhinoscopy and biopsy are performed. For rib tumors, fine-needle aspiration may be attempted, but a surgical biopsy is often needed. Staging includes thoracic radiographs or CT, abdominal ultrasound, and lymph node aspiration if enlarged.

Complete blood count (CBC) may show mild anemia of chronic disease or leukocytosis due to inflammation. Serum biochemistry profile may reveal elevated alkaline phosphatase (ALP) in some cases, but this is not specific. Hypercalcemia is rare. Urinalysis is usually unremarkable. Coagulation panel (PT/aPTT) is recommended to assess surgical risk, especially if a major resection is planned. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated but are not diagnostic. Synovial fluid analysis is not typically performed for bone tumors, but if a joint is involved, arthrocentesis may show a non-septic inflammatory response. For nasal tumors, cytology of nasal discharge may show neoplastic cells, but biopsy is required for definitive diagnosis. Histopathology is the gold standard, and immunohistochemistry may be used to differentiate chondrosarcoma from other sarcomas, with positive staining for S-100 and vimentin.

Radiography: Appendicular chondrosarcoma appears as a lytic, expansile lesion with cortical thinning and periosteal reaction. The periosteal reaction may be mild or absent, and there may be a soft tissue mass. Pathological fracture may be present. Nasal chondrosarcoma shows a soft tissue opacity within the nasal cavity, with lysis of the turbinates and possibly the nasal bones. CT is superior for evaluating the extent of nasal tumors, including invasion of the cribriform plate. MRI provides excellent soft tissue contrast and is useful for assessing intramedullary extension and soft tissue involvement. Ultrasonography may be used to evaluate soft tissue masses, but it is not the primary imaging modality for bone tumors. Bone scintigraphy can detect skeletal metastasis but is not specific. Angiography or fluoroscopy may be used for vascular studies, but they are rarely needed. For rib tumors, radiographs may show a mass with or without bone lysis. CT is helpful for surgical planning.

Cytology: Fine-needle aspiration of a bone mass may yield chondrocytes with varying degrees of atypia, but cytology is often non-diagnostic due to the dense matrix. For nasal tumors, cytology of nasal discharge may show neoplastic cells, but biopsy is required. Histopathology: The tumor is composed of lobules of neoplastic chondrocytes embedded in a cartilaginous matrix. The cells may be well-differentiated (grade I) with abundant matrix and low cellularity, or poorly differentiated (grade III) with high cellularity, nuclear pleomorphism, and mitotic activity. The mitotic index is an important prognostic indicator. Surgical margins should be evaluated for tumor-free margins. Special stains, such as Alcian blue or Safranin O, can highlight the cartilaginous matrix. Immunohistochemistry for S-100 protein is positive in chondrosarcoma, helping to differentiate it from other sarcomas.

The treatment of choice for chondrosarcoma is surgical excision with wide margins. For appendicular tumors, limb amputation is often recommended, especially for large, aggressive tumors. However, limb-sparing surgery may be considered for selected cases, particularly for low-grade tumors, but it requires extensive surgical expertise and adjuvant therapy. For nasal tumors, surgical debulking via rhinotomy or exenteration may be performed, but complete excision is often difficult due to the proximity to the cribriform plate. Radiation therapy may be used as an adjunct to surgery or as a primary treatment for non-resectable tumors. Chemotherapy (e.g., carboplatin, doxorubicin) may be considered for high-grade tumors or metastatic disease, but its efficacy is not well-established. For rib tumors, chest wall resection and reconstruction are performed. For pelvic tumors, hemipelvectomy may be necessary. Preoperative stabilization includes pain management and treatment of any concurrent conditions. Intraoperative complications include hemorrhage, which can be managed with ligation of vessels, electrocautery, or hemostatic agents. Postoperative pain management includes opioids (e.g., hydromorphone 0.05-0.1 mg/kg IV q4-6h), NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h), and local anesthetics (e.g., epidural analgesia). Physical rehabilitation is important for recovery.

The prognosis for chondrosarcoma is generally better than for osteosarcoma. For appendicular tumors, the median survival time after amputation is 1-3 years, with a 1-year survival rate of 60-80% and a 2-year survival rate of 40-60%. The metastatic rate is 10-20%, and metastasis is more common with high-grade tumors. For nasal tumors, the median survival time is 1-2 years, with a 1-year survival rate of 60-70%. Rib tumors have a good prognosis after complete excision, with a median survival time of 2-3 years. Negative prognostic indicators include high histological grade, incomplete surgical margins, and metastasis at diagnosis. Positive prognostic indicators include low-grade tumors, complete excision, and absence of metastasis.

Postoperative follow-up includes suture removal 10-14 days after surgery. Radiographs of the surgical site are recommended at 4, 8, and 12 weeks to assess healing and detect recurrence. Thoracic radiographs should be repeated every 3-6 months for the first 2 years to monitor for pulmonary metastasis. Physical examination should be performed at each visit, with attention to the surgical site and regional lymph nodes. Activity restriction is recommended for 4-6 weeks after amputation, with gradual return to normal activity. Physical therapy, including passive range of motion exercises and controlled leash walks, is beneficial. Long-term monitoring for limb function and quality of life is important. For nasal tumors, serial imaging (CT or MRI) may be needed to detect recurrence.

Pearls: 1) Always obtain thoracic radiographs before surgery to rule out metastasis. 2) For appendicular tumors, a biopsy is essential before amputation to confirm the diagnosis, as other tumors may have a different prognosis. 3) For nasal tumors, CT is essential for surgical planning to assess cribriform plate involvement. 4) Use a wide surgical margin (at least 2-3 cm) to reduce the risk of local recurrence. 5) For rib tumors, reconstruct the chest wall with a mesh or muscle flap to prevent respiratory compromise. Pitfalls: 1) Incomplete excision due to inadequate margins is a common cause of recurrence. 2) Failure to stage the patient may lead to missed metastasis. 3) In nasal tumors, aggressive surgery may cause significant morbidity, and radiation therapy may be a better option. 4) Overlooking the possibility of pathological fracture in appendicular tumors can lead to catastrophic failure. 5) Not considering the histological grade can lead to inappropriate treatment decisions.

Perioperative antimicrobial prophylaxis: Cefazolin 22 mg/kg IV at induction, repeated every 90 minutes during surgery. Postoperative antimicrobials are not routinely needed unless infection is present. Analgesia: Preoperative: Opioid (e.g., hydromorphone 0.05-0.1 mg/kg IV or morphine 0.5-1 mg/kg IM). Intraoperative: Fentanyl CRI (5-10 mcg/kg/hr) or lidocaine CRI (25-50 mcg/kg/min) for multimodal analgesia. Postoperative: Opioid (e.g., hydromorphone 0.05-0.1 mg/kg IV q4-6h) for 24-48 hours, then transition to oral opioids (e.g., tramadol 2-5 mg/kg PO q8-12h) if needed. NSAIDs: Carprofen 2.2 mg/kg PO q12h or meloxicam 0.1 mg/kg PO q24h, starting after surgery, for 3-7 days. Local anesthesia: Epidural with morphine (0.1 mg/kg) and bupivacaine (0.5-1 mg/kg) for hindlimb procedures. Muscle relaxants: Not routinely used. Chondroprotectants: Not indicated for tumor patients. For chemotherapy: Carboplatin 300 mg/m² IV every 3 weeks for 4-6 cycles, or doxorubicin 30 mg/m² IV every 3 weeks. Dosages should be adjusted based on renal and hepatic function.

Landmark studies: 1) A retrospective study by Straw et al. (1990) on appendicular chondrosarcoma in dogs reported a median survival time of 1.5 years after amputation, with a metastatic rate of 20%. 2) A study by Popovitch et al. (1994) on nasal chondrosarcoma found that surgical debulking followed by radiation therapy improved survival compared to surgery alone. 3) A study by Hammer et al. (1995) on rib chondrosarcoma reported a median survival time of 2.5 years after chest wall resection. 4) A consensus statement from the ACVS (American College of Veterinary Surgeons) recommends wide surgical excision as the primary treatment for chondrosarcoma, with radiation therapy for non-resectable tumors. 5) A meta-analysis by Selmic et al. (2014) on canine nasal tumors found that chondrosarcoma has a better prognosis than adenocarcinoma. 6) A study by Farese et al. (2009) on limb-sparing surgery for chondrosarcoma reported acceptable outcomes for low-grade tumors, but a high complication rate. 7) A study by Boston et al. (2006) on hemipelvectomy for pelvic tumors, including chondrosarcoma, showed that aggressive surgery can be curative with acceptable morbidity.